Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system

Abstract

The technology relates to a nucleic acid expression cassette comprising a TR element encoding an mRNA molecule that is translated in stressed and/or dying cells, and a nucleotide sequence operably linked to the TR element, that is a first open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element. The technology further relates to mammalian cells and a transgenic animal comprising such expression cassette. Further included are kits comprising the expression cassette, and methods for determining toxicity, and killing a target cell.

1 .- 122 . (canceled) 
     
     
         123 . A nucleic acid expression cassette expressible in mammalian cells, wherein the expression cassette comprises the following elements in a 5′ to 3′ direction:
 at least one transcriptional effector sequence, 
 a translational regulatory (TR) element encoding a mammalian mRNA molecule that is at least 80% homologous to a human Proteolipid Protein (plp) gene corresponding to nts 1-831 of a  FIG. 15  PLP sequence, and is selectively translated in stressed and/or dying cells, 
 a nucleotide sequence operably linked to the TR element, that is an open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element, and 
 a polyadenylation sequence, 
 wherein selectively translated in stressed and/or dying cells means that the mRNA translation activity is observed in more than 95% of any cell line transformed with the expression cassette at the peak of translation activity following treatment with an acute toxic agent that induces cell stress and/or death, and that translational levels of the ORF of the expression cassette rise to at least 50% of expression levels of the same ORF when transcribed and translated from the same expression cassette lacking an operably linked TR element following treatment with the acute toxic agent. 
 
     
     
         124 . The expression cassette of  claim 123 , wherein the TR element is from a mouse. 
     
     
         125 . The expression cassette of  claim 123 , wherein the transcriptional effector comprises a constitutive, inducible, tissue specific, tumor specific, or response gene promoter. 
     
     
         126 . The expression cassette of  claim 125 , wherein the promoter is a constitutive promoter selected from the group consisting of retroviral Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter, cytomegalovirus immediate early gene (CMV) promoter, simian virus early (SV40) promoter, cytoplasmic beta-actin promoter, adenovirus major late promoter, and phosphoglycerol kinase (PGK) promoter; an inducible promoter selected from the group consisting of human metallothionein II (hMT-IIA) promoter, dexamethasone (Dex)-inducible promoter, mouse mammary tumor virus (MMTV) promoter, ecdysone-responsive insect promoter, tetracycline responsive (Tet-On promoter, Tet-Off) promoter, mifepristone (RU486)-inducible promoter and rapamycin-responsive promoter; a tissue specific promoter selected from the group consisting of transferrin (TF) promoter, tyrosinase (TYR) promoter, albumin (ALB) promoter, muscle creatine kinase (CKM) promoter, mylin basic protein (MBP) promoter, glial fibrillary acidic protein (GFAP) promoter, neuron-specific enolase (NSE) promoter, and synapsin I (SYN1) promoter; a tumor specific promoter for vascular endothelial growth factor (VEGF), VEGF receptor (KDR), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (erbB2), mucin-1 (muc-1/DF3), ALA, bone gamma-carboxyglutamate protein (BGLAP), secretory leukoproteinase inhibitor or antileukoproteinase 1 (SLP1), hypoxia-response element (HRE), hexokinase II (Grp78/BIP, or HK2); or a response gene promoter for early growth response gene (EGR1), tissue-type plasminogen activator (t-PA), multidrug-resistance protein 1 (mdr-1), heat shock 70 kDa (hsp70), v-fos murine osteosarcoma viral oncogene homolog (c-fos), v-jun sarcoma virus 17 oncogene homolog (c-jun), E2F transcription factor 1 (E2F-1), heat shock 70 kDa protein 5 (HSPA5), cyclin A1 (CCNA1) or cell division cycle 25C (cdc25C). 
     
     
         127 . The expression cassette of  claim 123 , wherein the ORF sequence is selected from the group consisting of reporter gene, cytotoxic tumor suppressor, toxin gene, prodrug activating gene and proapoptotic gene. 
     
     
         128 . The expression cassette of  claim 127 , wherein the ORF sequence is a reporter gene. 
     
     
         129 . The expression cassette of  claim 128 , wherein the reporter gene is selected from the group consisting of egfp, gfp, eyfp, luciferase, lacZ, cat, tk, and tksr39. 
     
     
         130 . The expression cassette of  claim 129 , wherein the reporter gene is luciferase. 
     
     
         131 . The expression cassette of  claim 127 , wherein the ORF sequence is a cytotoxic tumor suppressor selected from the group consisting of p53, APC, BRCA-1, BRCA-2, WT-1, retinoblastoma, NF-1, NF-2 and VHL. 
     
     
         132 . The expression cassette of  claim 131 , wherein the cytotoxic tumor suppressor is p53. 
     
     
         133 . The expression cassette of  claim 127 , wherein the ORF sequence is a toxin gene selected from the group consisting of  pseudomonas  exotoxin, ricin toxin, and diptheria toxin. 
     
     
         134 . The expression cassette of  claim 133 , wherein the toxin gene is diphteria toxin. 
     
     
         135 . The expression cassette of  claim 127 , wherein the ORF sequence is a prodrug activating gene selected from the group consisting of TK and TKsr39. 
     
     
         136 . The expression cassette of  claim 135 , wherein the prodrug activating gene is TKsr39. 
     
     
         137 . The expression cassette of  claim 127 , wherein the ORF sequence is a proapoptotic gene selected from the group consisting of p53, ASPP1, ASPP2, ASPP3, Bax, BCL2-L-10, AIF, Fas, Caspase-8, Caspase-9, and Caspase-3. 
     
     
         138 . The expression cassette of  claim 137 , wherein the proapoptotic gene is p53. 
     
     
         139 . The expression cassette of  claim 123 , wherein the polyadenylation sequence is selected from the group consisting of SV40 early gene, SV40 late gene, HSV-TK, and hGH polyA tails. 
     
     
         140 . The expression cassette of  claim 123 , wherein the nucleotide sequence further comprises a 5′ untranslated region, which is located 3′ to the transcriptional effector sequence and 5′ to the TR element and comprises an mRNA transcription initiation site. 
     
     
         141 . The expression cassette of  claim 140 , wherein the 5′ untranslated region comprises an intron sequence which directs mRNA splicing. 
     
     
         142 . The expression cassette of  claim 123 , wherein the nucleotide acid sequence further comprises one or more of the following:
 a sequence of between about 15-50 nucleotides located 5′ to the transcriptional effector, that comprises one or more restriction sites for insertion of the cassette into a plasmid, shuttle vector or viral vector;   a sequence of between about 15-50 nucleotides located 3′ to the TR element and 5′ to the ORF sequence, that comprises one or more restriction sites for insertion and operative linkage of the TR element and the ORF sequence;   a sequence of between about 15-50 nucleotides located 3′ to the ORF sequence and 5′ to the polyadenylation sequence, that comprises one or more restriction sites for insertion and operative linkage of the ORF sequence and the polyadenylation sequence; or   a sequence of between about 15-50 nucleotides located 3′ to the polyadenylation sequence, that comprises one or more restriction sites for insertion of the cassette into a plasmid, shuttle vector or viral vector, wherein the addition of any of the sequences keeps translation in frame.   
     
     
         143 . The expression cassette of  claim 123 , wherein the expression cassette is contained in a plasmid, shuttle vector, or viral vector. 
     
     
         144 . The expression cassette of  claim 143 , wherein expression cassette is contained in a plasmid selected from the group consisting of pCMVneo, pCMV-MCS, pBluescript II, pET14, and pUC19; a shuttle vector selected from the group consisting of pCMV, pEYFP-N1, pEGFP-N1, and pEGFP-C1; or a viral vector selected from the group consisting of pAAV-MCS, pBac-1, and pBacPAK8/9. 
     
     
         145 . The expression cassette of  claim 144 , wherein the plasmid is pCMVneo. 
     
     
         146 . The expression cassette of  claim 144 , wherein the shuttle vector is pEYFP-N1. 
     
     
         147 . The expression cassette of  claim 144 , wherein the viral vector is pAAV-MCS. 
     
     
         148 . A mammalian cell that is transformed with the expression cassette of  claim 123 . 
     
     
         149 . The mammalian cell of  claim 148 , wherein the mammalian cell is selected from the group consisting of HEK293, HT1080, NTERA-2D, HeLa, Caco2, HepG2, BALBC/3T3, and Cos-7. 
     
     
         150 . The mammalian cell of  claim 148 , wherein the mammalian cell is an embryonic stem cell. 
     
     
         151 . The mammalian cell of  claim 150 , wherein the embryonic stem cell is a murine embryonic stem cell mES-D3 or human embryonic stem cell hES. 
     
     
         152 . The mammalian cell of  claim 148 , wherein the ORF sequence is selected from the group consisting of reporter gene, cytotoxic tumor suppressor, toxin gene, prodrug activating gene and proapoptotic gene. 
     
     
         153 . The mammalian cell of  claim 152 , wherein the ORF sequence is a reporter gene. 
     
     
         154 . The mammalian cell of  claim 153 , wherein the reporter gene is selected from the group consisting of EGFP, GFP, EYFP, luciferase, LacZ, CAT, TK, and TKsr39. 
     
     
         155 . The mammalian cell of  claim 154 , wherein the reporter gene is luciferase. 
     
     
         156 . A method for determining toxicity of a substance, wherein the method comprises:
 (a) contacting the mammalian cells of  claim 153  with the substance, wherein the ORF sequence encodes a reporter polypeptide; and   (b) detecting presence or measuring a level of the reporter polypeptide, wherein the toxicity of the substance correlates to the presence or the increase in the level of the reporter polypeptide as compared to control cells that are not exposed to the substance or are not transformed.   
     
     
         157 . The method of  claim 156 , wherein the protein level of the reporter polypeptide is measured. 
     
     
         158 . The method of  claim 156 , wherein the presence or levels of the mRNA of the reporter polypeptide are measured. 
     
     
         159 . The method of  claim 156 , wherein the step of contacting the mammalian cells is performed ex vivo. 
     
     
         160 . The method of  claim 156 , wherein the reporter polypeptide is luciferase. 
     
     
         161 . A method for determining toxicity of a substance to a mammal, wherein the method comprises:
 (a) transfecting a mammalian cell or a mammalian cell line with the expression cassette of  claim 128 , wherein the ORF sequence encodes a reporter polypeptide;   (b) contacting transfected cells from (a) with the substance; and   (c) detecting presence or measuring levels of the reporter polypeptide, wherein the toxicity of the substance correlates to the presence or the increase in the level of the reporter polypeptide as compared to control cells that are not exposed to the substance or are not transfected.   
     
     
         162 . The method of  claim 161 , wherein the protein level of the reporter polypeptide is measured. 
     
     
         163 . The method of  claim 161 , wherein the presence or levels of the mRNA of the reporter polypeptide are measured. 
     
     
         164 . The method of  claim 161 , wherein the reporter polypeptide is luciferase. 
     
     
         165 . A kit useful for toxicity assays comprising
 (a) the expression cassette of  claim 123 ; and   (b) instructions for use of the kit.   
     
     
         166 . A kit useful for toxicity assays comprising
 (a) the mammalian cells of  claim 148 ; and   (b) instructions for use of the kit.   
     
     
         167 . A transgenic non-human animal comprising the expression cassette of  claim 123  stably integrated into the genome of the animal. 
     
     
         168 . A method of inducing apoptosis in a target cell comprising transforming the cell with the expression cassette of  claim 131 , and exposing the transformed cell under toxic conditions. 
     
     
         169 . A method of inducing apoptosis in a target cell comprising transforming the cell with the expression cassette of  claim 133 , and exposing the transformed cell under toxic conditions. 
     
     
         170 . A method of inducing apoptosis in a target cell comprising transforming the cell with the expression cassette of  claim 135 , and exposing the transformed cell under toxic conditions. 
     
     
         171 . A method of inducing apoptosis in a target cell comprising transforming the cell with the expression cassette of  claim 137 , and exposing the transformed cell under toxic conditions. 
     
     
         172 . A method for detecting cell stress and/or apoptosis, wherein the method comprises:
 (a) obtaining the mammalian cells of  claim 153 , wherein the ORF sequence encodes a reporter polypeptide, or transfecting a mammalian cell or a mammalian cell line with the expression cassette of claim  6 , wherein the ORF sequence encodes a reporter polypeptide; and   (b) detecting presence or measuring a level of the reporter polypeptide, wherein the level of cell stress and/or apoptosis correlates to the presence or the increase in the level of the reporter polypeptide as compared to control cells that are not transfected.   
     
     
         173 . The method of  claim 172 , wherein the method includes prior to step (b) a step of contacting the mammalian cells with a substance capable of inducing cell stress and/or apoptosis. 
     
     
         174 . The method of  claim 172 , wherein the protein level of the reporter polypeptide is measured or the presence or levels of the mRNA of the reporter polypeptide are measured. 
     
     
         175 . The method of  claim 172 , wherein the reporter polypeptide is luciferase. 
     
     
         176 . A method for inhibiting apoptosis in a mammalian cell comprising transforming the mammalian cell with the expression cassette of  claim 123  wherein the ORF sequence encodes an antiapoptotic protein. 
     
     
         177 . The method of  claim 176 , wherein the antiapoptotic protein is selected from the group consisting of BCL2, BCL2L1, BCL2A1, BAG1, TRAF1, BIRC3, BIRC5, BAK1, and API5. 
     
     
         178 . A pharmaceutical composition comprising the expression cassette of  claim 123  and a pharmaceutically acceptable carrier.